Basic science and research in renal cell carcinoma: From workbench to bedside

Current Opinion in Urology

Volumn 13, Issue 6, 2003, Pages 457-462

  Heidenreich, Axel ^a   Schrader, Andres J ^a   Varga, Zoltan ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Angiogenesis; Antisense oligodeoxynucleotide therapy; Apoptosis; Monoclonal antibody therapy; Prognostic risk factors; Renal cell cancer

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTOKINE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEASOME INHIBITOR; SCLEROPROTEIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER RESEARCH; CANCER RISK; CANCER SURGERY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; GENE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KIDNEY CARCINOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCIENCE; TRANSDUCER;

BIOMEDICAL RESEARCH; CARCINOMA, RENAL CELL; CYSTEINE ENDOPEPTIDASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY NEOPLASMS; MOLECULAR BIOLOGY; MULTIENZYME COMPLEXES; OLIGONUCLEOTIDES, ANTISENSE; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0442292065     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200311000-00006     Document Type: Review

References (26)

1. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-1623.
2. Uemura H, Hirao Y. Clinical significance for detection of circulating cancer cells in renal cell carcinoma [in Japanese]. Gan To Kagaku Ryoho 2002; 29:1712-1718.
3. Gilbert SM, Whitson JM, Manshukani M, et al. MN/CAIX expression predicts disease free survival in renal cell carcinoma. Proc ASCO 2003; 22:418, #1680.
4. Heidenreich A, Schrader AJ, Ohlmann C, et al. Reverse transcription PCR assay for g250 to detect circulating tumor cells in renal cell carcinoma: results of a prospective randomised trial. Eur Urol 2003; (Suppl 2):179, #708.
5. von Knobloch R, Hegele A, Brandt H, et al. High frequency of serum DNA alterations in renal cell carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 2002; 98:889-894.
6. Ashida S, Furihata M, Tanimura M, et al. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status. J Urol 2003; 169:2089-2093.
7. Sherief MH, Low SH, Miura M, et al. Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay. J Urol 2003; 169:1530-1534.
8. Méjean A, Oudard S, Thiounn N. Prognostic factors of renal cell carcinoma. J Urol 2003; 169:821-827.
9. Horiguchi A, Oya M, Shimada T, et al. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 2002; 168:762-765.
10. Ellerhorst JA, Hildebrand WA, Cavett JW, et al. Heterozygosity or homozygosity for HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy. J Urol 2003; 169:2084-2088.
11. Palapattu GS, Reiter RE. Monoclonal antibody therapy for genitourinary oncology: promise for the future. J Urol 2002; 168:2615-2623. This is an excellent review of the current status, limitations and future perspectives of the clinical application of monoclonal antibody-based therapy.
12. Stadick H, Stockmeyer B, Kühn R, et al. Epidermal growth factor receptor and G250: useful target antigens for antibody mediated cellular cytotoxicty against renal cell carcinoma? J Urol 2002; 167:707-712.
13. Dawson NA, Guo C, Zak R, et al. A phase II trial of ZD 1839 in stage IV and recurrent renal cell carcinoma. Proc ASCO 2003; 22:404, #1623.
14. Jermann M, Joerger M, Pless M, et al. An open-label phase II trial to evaluate the efficacy and safety of gefinitib in patients with locally advanced, relapsed or metastatic renal cell cancer. Proc ASCO 2003; 22:418, #1681.
15. George D, Michaelson D, Oh WK, et al. Phase I study of PTK787/ZK222584 in metastatic renal cell carcinoma. Proc ASCO 2003; 22:385, #1548.
16. Eisen T. Phase II results of a phase II/III study comparing thalidomide with medroxyprogesterone in patients with metastatic renal cell carcinoma. Proc ASCO 2003; 22:400, #1606.
17. Olencki T, Mahli S, Mekhail T, et al. Phase I trial of thalidomide and interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. Proc ASCO 2003; 22:387, #1554.
18. Amato RJ, Schell J, Thompson N, et al. Phase II study of thalidomide and interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. Proc ASCO 2003; 22:387, #1556.
19. Sella A, Sternberg C, Yarom N, et al. Phase II study of low dose thalidomide and interferon-arfa in metastatic renal cell carcinoma. Proc ASCO 2003; 22:402, #1614.
20. Kausch I, Böhle A. Antisense oligonucleotide therapy in urology. J Urol 2002; 168:239-247. This is an excellent review of the current status, limitations and future perspectives of the clinical application of antisense oligodeoxynucelotide therapy in modern urological oncology.
21. Lee CH, Jin RJ, Kwak C, et al. Suppression of clusterin expression enhanced cisplatin-induced cytotoxicity on renal cell carcinoma cells. Urology 2002; 60:516-520. This paper represents a well-designed and performed in-vitro study with potential use in future clinical trials on RCC.
22. Uchida T, Gao JP, Wang C, et al. Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucelotides on human renal-cell carcinoma cells in vitro and in mice. Mol Urol 2001; 5:71-78.
23. Shi W, Siemann DW. Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br J Cancer 2002; 87:119-126. This paper is a well-performed in-vitro study being transferred into an experimental animal model in anticipation of the development of a clinically useful therapeutic approach.
24. Mitchell BS. The proteasome - an emerging therapeutic target in cancer. N Engl J Med 2003; 348:2597-2598.
25. Drucker BJ, Schwartz L, Bacik J, et al. Phase II trial of PS-341 shows response in patients with advanced renal cell carcinoma. Proc ASCO 2003; 22:386, #1550.
26. Davis NB, Taber DA, Ansari RH, et al. A phase II trial of PS-341 in patients with renal cell cancer. Proc ASCO 2003; 22:386, #1551.